As advocates for Alzheimer's research swarmed Capitol Hill this week, they told lawmakers, in polite terms, to put federal funding where their mouths are. Read More
TAIPEI, Taiwan – With the number of confirmed H7N9 infections cases in China currently at 108 and 22 deaths, Taiwan confirmed its first case of H7N9 avian influenza infection – a 53-year-old Taiwanese returning to the island on April 9 after working in China's Jiangsu province. Meanwhile, viral material for use in both creating more accurate diagnostic kits and for vaccine production arrived in Taiwan, sent courtesy of Chinese health authorities. Read More
CHICAGO – This could be a very good year for deals, according to data from the Biotechnology Industry Organization (BIO) and biopharma consulting firm Campbell Alliance Group that were presented during a super session on structuring pipeline deals. Read More
Biogen Idec Inc. reported total revenues of $1.4 billion in the first quarter of 2013, a 10 percent increase compared to the first quarter of 2012. Read More
CHICAGO – The BIO International Convention is always full of memorable moments. This year was no different. Here, members of BioWorld Today's team share vignettes, quotes and afterthoughts captured through the week in the Windy City. Read More
Genticel SA raised €18.2 million (US$23.6 million) in a Series C round led by Wellington Partners, to move ProCervix, its bivalent therapeutic vaccine for combating human papillomavirus (HPV) infection into Phase II trials. Read More
• OvaScience, of Cambridge, Mass, said its common stock was approved for listing on Nasdaq under the ticker "OVAS" and will start trading April 30. Read More
• Medgenics Inc., of San Francisco, said there have not been any procedure- or drug-related serious adverse events in the first four patients treated in the Phase IIa trial in Israel of Epodure biopumps for anemia in those on dialysis with end-stage renal disease. Read More
• Actavis Inc., of Parsippany, N.J., reached a settlement agreement with Shire plc, of Dublin, Ireland, resolving patent litigation related to Actavis' generic version of INTUNIV (guanfacine hydrochloride) to treat attention deficit hyperactivity disorder. In October 2012, the FDA granted approval of Actavis' abbreviated new drug application. Read More
• Pfizer Inc., of New York, said that top-line data for a Phase IV trial of Celebrex (celecoxib) capsules or naproxen in juvenile idiopathic arthritis patients demonstrated no difference in changes to systolic blood pressure, the primary endpoint, and diastolic blood pressure, the secondary endpoint. Read More
